Ian Ingram is a Deputy Managing Editor at MedPage Today. He covers a range of topics within medicine and healthcare, focusing on consumer health, drugs and medication, public health, and the healthcare system, with a particular interest in alternative medicine. Ian's work has been featured in Knowledia, ExBulletin, MedPage Today, and MSN.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Ian Ingram's coverage is primarily focused on healthcare and pharmaceuticals, with a particular emphasis on clinical trial results, FDA approvals, and drug treatments for cancer and leukemia. He frequently cites data in his articles, indicating an interest in evidence-based reporting.
Pitching to Ian should involve providing access to newly released or exclusive clinical trial data, insights from key opinion leaders in the field of oncology or pharmaceuticals regarding recent developments in cancer treatment or FDA approval processes.
It's important to note that Ian does not have a specific geographic focus but covers international healthcare and pharmaceutical topics.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Ian Ingram
News and commentary from the world of gastroenterology and hepatology
Studies have shown baloxavir to be a standout among antivirals commonly used for influenza
By: Ian Ingram
— News and commentary from the world of gastroenterology and hepatology
A European Medicines Agency (EMA) committee recommended pulling the marketing authorization opens in a new tab or window for avacopan (Tavneos) following
IL-23 inhibitor lands indications for kids 6 years and up
Move follows actions 'inconsistent with proper research conduct,' journal says
By: Ian Ingram
A novel lead flap-enhanced artificial intelligence-enabled fluoroscopy system may lower the risk of radiation scatter opens in a new tab or window
By: Ian Ingram
News and commentary from the world of gastroenterology and hepatology
By: Ian Ingram
Ian Ingram Diabetes patients with hepatocellular carcinoma (HCC) experienced longer time to HCC recurrence and longer survival when they
— IMACS guidelines are clinically useful for identifying high-risk populations, researchers say
